Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Office of Science and Data Policy (SDP)

The Office of Science and Data Policy is the departmental focal point for policy research, analysis, evaluation, and coordination of department-wide public health science policy and data policy activities and issues. The Office provides authoritative advice and analytical support to the ASPE and departmental leadership on public health science policy and data policy issues and initiatives, coordinates science and data policy issues of interagency scope within HHS, and manages interagency initiatives in science policy and data policy. The Office works closely with staff from across the Department on strategic plan development and implementation efforts. The Offices also carries out a program of policy research, analysis, evaluation, and data development in these issues.

The Office of Science and Data Policy includes several components:

Topic Areas:

  • HHS Data Council
  • Regulatory Impact Analysis
  • Strategic Planning
  • Information Quality Guidelines
  • Prevention and wellness
  • Public health systems and functions
  • Food safety and nutrition
  • Drugs and devices
  • Tobacco control and prevention
  • Biomedical research and development
  • Economic analysis
  • Emergency preparedness, response, and recovery
  • Data and statistical policy
  • Health disparities and vulnerable populations
  • Health information technology
  • Microsimulation
  • Privacy policy

Reports

Displaying 11 - 20 of 129. 10 per page. Page 2.

Advanced Search
Report

FY 2023-2026 HHS Capacity Assessment

March 28, 2022
Under the Foundations for Evidence-Based Policymaking Act of 2018 (Evidence Act), the Capacity Assessment requires agencies to assess the coverage, quality, methods, effectiveness, and independence of their statistics, evaluation, research, and analysis efforts.
Report

FY 2023-2026 HHS Evidence-Building Plan

March 28, 2022
The HHS Evidence Building Plan, required by the Evidence Act, is a systematic plan for identifying and addressing policy questions relevant to the programs, policies, and regulations of the agency.
ASPE Issue Brief

Demographic Characteristics of Adults Receiving COVID-19 Booster Vaccinations

March 18, 2022
This ASPE issue brief examines demographic characteristics of adults receiving booster doses of COVID-19 vaccines using data from the U.S. Census Bureau's Household Pulse Survey. As of March 9, 2022, 47.5 percent of the fully vaccinated adult population has received a booster.
Report

Cost of Generic Drug Development and Approval

February 3, 2022
The purpose of this study was to estimate the cost of generic drug development and approval. This study develops an analytical framework for examining the expected net present value (ENPV) (i.e., the difference between the present value of expected revenues over product life and cost of product development and approval) to a generic drug developer in different size drug markets.
ASPE Issue Brief

Parents’ Intentions to Vaccinate Children for COVID-19 by Child Age: Sociodemographic Factors and Reasons for Hesitancy

February 2, 2022
This ASPE issue brief examines hesitancy among parents to vaccinate children ages 5-11 and 12-17 using data from the U.S. Census Bureau's Household Pulse Survey. Overall, a larger percent of parents with children aged 5-11 are hesitant to vaccinate their children (34 percent) than parents of children aged 12-17 (21 percent).
ASPE Issue Brief

Variation in use of anti-SARS-CoV-2 monoclonal antibody therapies by social vulnerability and urbanicity

December 29, 2021
Anti-SARS-CoV-2 monoclonal antibodies are an effective treatment to prevent progression to severe COVID-19 or hospitalization in high-risk individuals. Despite the benefits offered by monoclonal antibody treatment, early reports indicated that these therapeutics were not being widely used.
Research Brief

COVID-19 Vaccination Associated with Reductions in COVID-19 Mortality and Morbidity in the United States, and an Approach to Valuing these Benefits

December 15, 2021
This ASPE Research Report models the estimated reductions in COVID-19 cases, hospitalizations, and deaths associated with COVID-19 vaccination from December 2020 through July 2021. To download the Research Report, please download the PDF to the right under “Files”. To explore our dashboard that presents the Report’s results, please see below.
ASPE Issue Brief

U.S. Department of Health and Human Services Overdose Prevention Strategy

October 27, 2021
From 1999 through 2019, there were more than 840,000 drug overdose deaths in the United States. The crisis has continually evolved and escalated, including during the COVID-19 pandemic, when an estimated 93,000 persons lost their lives to drug overdose in 2020--approximately a 30% increase over the year prior.
Report

Addressing Uncertainty in Regulatory Impact Analysis

October 15, 2021
In 2016, the U.S. Department of Health and Human Services finalized its Guidelines for Regulatory Impact Analysis under the leadership of its Assistant Secretary for Planning Evaluation and Analytics Team. The Guidelines discuss strategies for characterizing the uncertainty in quantified effects as well as the potential impacts of non-quantified effects.
Report

Prescription Drug Supply Chains: An Overview of Stakeholders and Relationships

October 14, 2021
Many stakeholders and steps are involved in the life cycle of a prescription drug as it moves from chemical synthesis and formulation through dispensing or administration to patients. The specific steps involved in prescription drug supply chains often differ depending on the type of drug, the channel of distribution, and the patient’s source of prescription drug coverage.